A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Juno Therapeutics

Status and phase: Enrolling; Phase 1

Conditions: Multiple Myeloma

Treatments: Drug: Alnuctamab; Drug: Iberdomide; Drug: Mezigdomide; Drug: BMS-986393

Study type: Interventional

Funder types: Industry

Identifiers

NCT06121843

CA088-1005

Details and patient eligibility

About

The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).

Enrollment: 111 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1 and Part 2) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2)
• Measurable multiple myeloma (MM)
• Eastern Cooperative Oncology Group performance status of 0-1

Exclusion criteria

• Condition that confounds the ability to interpret data from the study
• Known active or history of central nervous system (CNS) involvement of MM

Note: Other protocol-defined inclusion/exclusion criteria apply

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

111 participants in 3 patient groups

Arm A: BMS-986393 + Alnuctamab

Experimental group

Treatment:

Drug: BMS-986393

Drug: Alnuctamab

Arm B: BMS-986393 + Mezigdomide

Experimental group

Treatment:

Drug: BMS-986393

Drug: Mezigdomide

Arm C: BMS-986393 + Iberdomide

Experimental group

Treatment:

Drug: BMS-986393

Drug: Iberdomide